CPA_Venous Thromboembolism (VTE) and Direct Acting Oral Anticoagulants (DOAC) Therapies in Care of HIV Clients


Date: Jul 23, 2024 12:00 PM - 01:30 PM

Fee

$0.00

CE Hours

1.50

CE Units

0.150

Registration closes on Jul 29, 2024 10:00 PM

Activity Type

Knowledge

Target Audience(s)

Pharmacist

Accreditation(s)

Accreditation Council for Pharmacy Education
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Registration Closed  

Objectives

  • Describe the common causes and relative risk of venothromboembolism (VTE) in persons living with human immunodeficiency virus (PLWH).
  • Identify and discuss the pharmacotherapy and formulary management considerations for the FDA-approved direct- acting oral anticoagulants (DOACs) including dabigatran, rivaroxaban, apixaban and endoxaban.
  • Given a clinical case of a PLWH with a diagnosis of VTE, outline pharmaceutical care actions needed to promote safe and effective management of a DOAC including dosing, drug interaction management, transitions of care and bleeding.

Speaker(s)/Author(s)

Dr. Christopher Keeys, Pharm.D.,BCPS, Pharm.D., BCPS
President, Clinical Pharmacy Associates, Inc.

Activity Number

0010-9999-24-044-L01-P
Date: 07/23/24
Time: 12:00 PM - 01:30 PM

CE Hours

1.50
Registration Closed